Cartesian Therapeutics announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company’s common stock with an exercise price of $36.00, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on June 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Announces New Employment Inducement Grant
- Flutter initiated, SentinelOne upgraded: Wall Street’s top analyst calls
- Cartesian Therapeutics initiated with an Outperform at Oppenheimer
- Cartesian Therapeutics initiated with a Buy at Mizuho
- Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis